WO2023055178A1 - 신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물 - Google Patents
신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물 Download PDFInfo
- Publication number
- WO2023055178A1 WO2023055178A1 PCT/KR2022/014774 KR2022014774W WO2023055178A1 WO 2023055178 A1 WO2023055178 A1 WO 2023055178A1 KR 2022014774 W KR2022014774 W KR 2022014774W WO 2023055178 A1 WO2023055178 A1 WO 2023055178A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- piperidin
- dihydro
- inden
- amine
- pyrimidin
- Prior art date
Links
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 title claims abstract description 44
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 230000002401 inhibitory effect Effects 0.000 title abstract description 20
- 150000003053 piperidines Chemical class 0.000 title description 5
- -1 piperidine derivative compound Chemical class 0.000 claims abstract description 321
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 239000012453 solvate Substances 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 13
- 230000001684 chronic effect Effects 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 8
- 206010027476 Metastases Diseases 0.000 claims abstract description 7
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 7
- 230000009401 metastasis Effects 0.000 claims abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 6
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 6
- 210000000056 organ Anatomy 0.000 claims abstract description 6
- 208000003251 Pruritus Diseases 0.000 claims abstract description 5
- 206010052779 Transplant rejections Diseases 0.000 claims abstract description 5
- 230000001154 acute effect Effects 0.000 claims abstract description 5
- 208000022873 Ocular disease Diseases 0.000 claims abstract description 3
- 230000001587 cholestatic effect Effects 0.000 claims abstract 3
- 150000001875 compounds Chemical class 0.000 claims description 170
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 6
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 6
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims description 5
- 206010016654 Fibrosis Diseases 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000016097 disease of metabolism Diseases 0.000 claims description 5
- 230000004761 fibrosis Effects 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 230000002107 myocardial effect Effects 0.000 claims description 4
- SMXMELMJCICPJG-UHFFFAOYSA-N piperidine-4-sulfonamide Chemical compound NS(=O)(=O)C1CCNCC1 SMXMELMJCICPJG-UHFFFAOYSA-N 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 3
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- FJRPOHLDJUJARI-UHFFFAOYSA-N 2,3-dihydro-1,2-oxazole Chemical compound C1NOC=C1 FJRPOHLDJUJARI-UHFFFAOYSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000001344 Macular Edema Diseases 0.000 claims description 2
- 206010025415 Macular oedema Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 2
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010038923 Retinopathy Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 206010050207 Skin fibrosis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010058990 Venous occlusion Diseases 0.000 claims description 2
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000037849 arterial hypertension Diseases 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 239000010425 asbestos Substances 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000005518 carboxamido group Chemical group 0.000 claims description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 2
- 206010061989 glomerulosclerosis Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 230000009545 invasion Effects 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229910052895 riebeckite Inorganic materials 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 201000006397 traumatic glaucoma Diseases 0.000 claims description 2
- 230000008736 traumatic injury Effects 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000003966 vascular damage Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000006806 disease prevention Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 139
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 136
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 108
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 107
- 238000005481 NMR spectroscopy Methods 0.000 description 72
- 239000000203 mixture Substances 0.000 description 64
- 239000007787 solid Substances 0.000 description 64
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
- 239000011541 reaction mixture Substances 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 58
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 57
- 239000000243 solution Substances 0.000 description 47
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 43
- LMHHFZAXSANGGM-UHFFFAOYSA-N 2-aminoindane Chemical compound C1=CC=C2CC(N)CC2=C1 LMHHFZAXSANGGM-UHFFFAOYSA-N 0.000 description 40
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 39
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 39
- 235000019439 ethyl acetate Nutrition 0.000 description 36
- 238000004440 column chromatography Methods 0.000 description 32
- 239000012044 organic layer Substances 0.000 description 32
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- LGIWBPLJDKOQSX-UHFFFAOYSA-N 4-(2h-triazol-4-yl)piperidine Chemical compound C1CNCCC1C1=NNN=C1 LGIWBPLJDKOQSX-UHFFFAOYSA-N 0.000 description 28
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 25
- 239000002904 solvent Substances 0.000 description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 23
- 239000011734 sodium Substances 0.000 description 23
- 239000012267 brine Substances 0.000 description 21
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- FFXAFFLFBBVZOC-UHFFFAOYSA-N 1h-inden-2-amine Chemical compound C1=CC=C2CC(N)=CC2=C1 FFXAFFLFBBVZOC-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 239000000741 silica gel Substances 0.000 description 14
- 229910002027 silica gel Inorganic materials 0.000 description 14
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- QOCUGSJAOYAVQE-UHFFFAOYSA-N 5,6-difluoro-2,3-dihydro-1h-inden-2-amine Chemical compound FC1=C(F)C=C2CC(N)CC2=C1 QOCUGSJAOYAVQE-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 10
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 238000010898 silica gel chromatography Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 7
- VEIWYFRREFUNRC-UHFFFAOYSA-N hydron;piperidine;chloride Chemical compound [Cl-].C1CC[NH2+]CC1 VEIWYFRREFUNRC-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- VAAFFDVGGMHGHW-UHFFFAOYSA-N 5-fluoro-2,3-dihydro-1h-inden-2-amine Chemical compound C1=C(F)C=C2CC(N)CC2=C1 VAAFFDVGGMHGHW-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 108010022198 alkylglycerophosphoethanolamine phosphodiesterase Proteins 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- INUWDZDWSJJFSQ-UHFFFAOYSA-N tert-butyl 4-ethynylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C#C)CC1 INUWDZDWSJJFSQ-UHFFFAOYSA-N 0.000 description 5
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- VUAXHMVRKOTJKP-UHFFFAOYSA-M 2,2-dimethylbutanoate Chemical compound CCC(C)(C)C([O-])=O VUAXHMVRKOTJKP-UHFFFAOYSA-M 0.000 description 4
- VEUMBMHMMCOFAG-UHFFFAOYSA-N 2,3-dihydrooxadiazole Chemical compound N1NC=CO1 VEUMBMHMMCOFAG-UHFFFAOYSA-N 0.000 description 4
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- OAXDQMGGHLSHRF-UHFFFAOYSA-N methyl piperidine-4-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.COC(=O)C1CCNCC1 OAXDQMGGHLSHRF-UHFFFAOYSA-N 0.000 description 4
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- PHLZUDXEBCQHKM-UHFFFAOYSA-N (3,4-difluorophenyl)methanamine Chemical compound NCC1=CC=C(F)C(F)=C1 PHLZUDXEBCQHKM-UHFFFAOYSA-N 0.000 description 3
- OKWATXMSXLFWAN-UHFFFAOYSA-N 1-(2h-triazol-4-yl)piperidine Chemical compound C1CCCCN1C1=CNN=N1 OKWATXMSXLFWAN-UHFFFAOYSA-N 0.000 description 3
- KFJYLCFNRATSPE-UHFFFAOYSA-N 4-(1,2,4-triazol-1-yl)piperidine Chemical compound C1CNCCC1N1N=CN=C1 KFJYLCFNRATSPE-UHFFFAOYSA-N 0.000 description 3
- RWAVYCTUVYJSMU-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-inden-2-amine Chemical compound C1=C(Br)C=C2CC(N)CC2=C1 RWAVYCTUVYJSMU-UHFFFAOYSA-N 0.000 description 3
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000897035 Homo sapiens Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- MEJGIRNNNFPMOX-UHFFFAOYSA-N azidomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCN=[N+]=[N-] MEJGIRNNNFPMOX-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- IEMKQRSOAOPKRJ-UHFFFAOYSA-N ethyl 2-chloropyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1 IEMKQRSOAOPKRJ-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- SNWQUNCRDLUDEX-UHFFFAOYSA-N inden-1-one Chemical compound C1=CC=C2C(=O)C=CC2=C1 SNWQUNCRDLUDEX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VUYZDLSEMFYUEY-UHFFFAOYSA-N tert-butyl 4-(1,2,4-triazol-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1N=CN=C1 VUYZDLSEMFYUEY-UHFFFAOYSA-N 0.000 description 3
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 3
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- ICIJWOWQUHHETJ-UHFFFAOYSA-N (3,5-dichlorophenyl)methanamine Chemical compound NCC1=CC(Cl)=CC(Cl)=C1 ICIJWOWQUHHETJ-UHFFFAOYSA-N 0.000 description 2
- ZILSBZLQGRBMOR-UHFFFAOYSA-N 1,3-benzodioxol-5-ylmethanamine Chemical compound NCC1=CC=C2OCOC2=C1 ZILSBZLQGRBMOR-UHFFFAOYSA-N 0.000 description 2
- PTZNCCIULVXFIJ-UHFFFAOYSA-N 1-o-tert-butyl 4-o-methyl piperidine-1,4-dicarboxylate Chemical compound COC(=O)C1CCN(C(=O)OC(C)(C)C)CC1 PTZNCCIULVXFIJ-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NNDJCSXUAYKMAA-UHFFFAOYSA-N 4-(1h-imidazol-5-yl)piperidine Chemical compound C1CNCCC1C1=CN=CN1 NNDJCSXUAYKMAA-UHFFFAOYSA-N 0.000 description 2
- UAWMVMPAYRWUFX-UHFFFAOYSA-N 6-Chloronicotinic acid Chemical compound OC(=O)C1=CC=C(Cl)N=C1 UAWMVMPAYRWUFX-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 229910018072 Al 2 O 3 Inorganic materials 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- XJNJPQSXRUJCIB-UHFFFAOYSA-N ethyl 2-chloro-4-methylpyrimidine-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)N=C1C XJNJPQSXRUJCIB-UHFFFAOYSA-N 0.000 description 2
- ILDJJTQWIZLGPO-UHFFFAOYSA-N ethyl 6-chloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=C1 ILDJJTQWIZLGPO-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- NVHXMNNCHAFIHX-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=C=N[N]1 NVHXMNNCHAFIHX-UHFFFAOYSA-N 0.000 description 2
- UOYSTPYCLSTYPU-UHFFFAOYSA-N pyrimidine-5-carbohydrazide Chemical compound NNC(=O)C1=CN=CN=C1 UOYSTPYCLSTYPU-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000010517 secondary reaction Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- YATXQENSVJAHPY-UHFFFAOYSA-N tert-butyl 4-(2h-tetrazol-5-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=NN=NN1 YATXQENSVJAHPY-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IYXUFOCLMOXQSL-UHFFFAOYSA-N (2,2-difluoroacetyl) 2,2-difluoroacetate Chemical compound FC(F)C(=O)OC(=O)C(F)F IYXUFOCLMOXQSL-UHFFFAOYSA-N 0.000 description 1
- KLLYGDXCCNXESW-UHFFFAOYSA-N (2-fluoroacetyl) 2-fluoroacetate Chemical compound FCC(=O)OC(=O)CF KLLYGDXCCNXESW-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- IXHNFOOSLAWRBQ-UHFFFAOYSA-N (3,4-dichlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C(Cl)=C1 IXHNFOOSLAWRBQ-UHFFFAOYSA-N 0.000 description 1
- UDXPHDTYBGZDNT-UHFFFAOYSA-N (3,5-dibromophenyl)methanamine Chemical compound NCC1=CC(Br)=CC(Br)=C1 UDXPHDTYBGZDNT-UHFFFAOYSA-N 0.000 description 1
- VJNGGOMRUHYAMC-UHFFFAOYSA-N (3,5-difluorophenyl)methanamine Chemical compound NCC1=CC(F)=CC(F)=C1 VJNGGOMRUHYAMC-UHFFFAOYSA-N 0.000 description 1
- DQFOSYRXEOWKOY-UHFFFAOYSA-N (3-methylsulfonylphenyl)methanamine Chemical compound CS(=O)(=O)C1=CC=CC(CN)=C1 DQFOSYRXEOWKOY-UHFFFAOYSA-N 0.000 description 1
- VMNXLLDFGVEBLE-UHFFFAOYSA-N (4-methylsulfonylphenyl)methanamine Chemical compound CS(=O)(=O)C1=CC=C(CN)C=C1 VMNXLLDFGVEBLE-UHFFFAOYSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- BSTAWYYHYJYBIZ-UHFFFAOYSA-N 1-(1h-imidazol-5-yl)piperidine Chemical compound C1CCCCN1C1=CNC=N1 BSTAWYYHYJYBIZ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- MHCWBHMMWDDZFI-UHFFFAOYSA-N 1-piperidin-4-ylazetidin-3-ol Chemical compound C1C(O)CN1C1CCNCC1 MHCWBHMMWDDZFI-UHFFFAOYSA-N 0.000 description 1
- KWRSKZMCJVFUGU-UHFFFAOYSA-N 1h-inden-1-ol Chemical compound C1=CC=C2C(O)C=CC2=C1 KWRSKZMCJVFUGU-UHFFFAOYSA-N 0.000 description 1
- TXEUPGABAVOGIG-UHFFFAOYSA-N 1h-inden-2-ol Chemical compound C1=CC=C2CC(O)=CC2=C1 TXEUPGABAVOGIG-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JVOHBPFLXAVCDU-UHFFFAOYSA-N 2-(3,4-difluorophenyl)propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(F)C(F)=C1 JVOHBPFLXAVCDU-UHFFFAOYSA-N 0.000 description 1
- HEEUTZAJXBKBEJ-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)ethanamine Chemical compound NCCC1=CC(Cl)=CC(Cl)=C1 HEEUTZAJXBKBEJ-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- JUYQWJULYXCBAV-UHFFFAOYSA-N 2-chloropyrimidine-5-carbonyl chloride Chemical compound ClC(=O)C1=CN=C(Cl)N=C1 JUYQWJULYXCBAV-UHFFFAOYSA-N 0.000 description 1
- DUCXUPKLVVSJKA-UHFFFAOYSA-N 2-chloropyrimidine-5-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)N=C1 DUCXUPKLVVSJKA-UHFFFAOYSA-N 0.000 description 1
- YDKMMXBPUCTFTD-UHFFFAOYSA-N 2-piperidin-4-yl-1,3,4-oxadiazole Chemical compound C1CNCCC1C1=NN=CO1 YDKMMXBPUCTFTD-UHFFFAOYSA-N 0.000 description 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 1
- NHYJRLYFKZYPMO-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=C(Cl)C(Cl)=C1 NHYJRLYFKZYPMO-UHFFFAOYSA-N 0.000 description 1
- DDDFLVOQZPSQPV-UHFFFAOYSA-N 3-(3,4-difluorophenyl)propanoyl chloride Chemical compound FC1=CC=C(CCC(Cl)=O)C=C1F DDDFLVOQZPSQPV-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- MRDDTHJHBTYISC-UHFFFAOYSA-N 3-piperidin-4-yl-1,2,4-oxadiazole;hydrochloride Chemical compound Cl.C1CNCCC1C1=NOC=N1 MRDDTHJHBTYISC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XXQLYFSAITYKAV-UHFFFAOYSA-N 4-(3-methyl-1,2,4-triazol-1-yl)piperidine Chemical compound N1=C(C)N=CN1C1CCNCC1 XXQLYFSAITYKAV-UHFFFAOYSA-N 0.000 description 1
- BEQPNOLGWGPSPN-UHFFFAOYSA-N 4-(tetrazol-1-yl)piperidine Chemical compound C1CNCCC1N1N=NN=C1 BEQPNOLGWGPSPN-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- TYMKPEDIRMEEQH-UHFFFAOYSA-N 4-ethynylpiperidine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C#CC1CCNCC1 TYMKPEDIRMEEQH-UHFFFAOYSA-N 0.000 description 1
- WZKLBUYGIBQZPJ-UHFFFAOYSA-N 4-ethynylpiperidine;hydrochloride Chemical compound Cl.C#CC1CCNCC1 WZKLBUYGIBQZPJ-UHFFFAOYSA-N 0.000 description 1
- YYBXNWIRMJXEQJ-UHFFFAOYSA-N 4-piperidin-4-ylmorpholine Chemical compound C1CNCCC1N1CCOCC1 YYBXNWIRMJXEQJ-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GWWRJUWUQCIBET-UHFFFAOYSA-N 5,6-dibromo-2,3-dihydro-1h-inden-2-amine Chemical compound BrC1=C(Br)C=C2CC(N)CC2=C1 GWWRJUWUQCIBET-UHFFFAOYSA-N 0.000 description 1
- YXQCOYQBWHHOPI-UHFFFAOYSA-N 5,6-dichloro-1h-indene Chemical compound C1=C(Cl)C(Cl)=CC2=C1C=CC2 YXQCOYQBWHHOPI-UHFFFAOYSA-N 0.000 description 1
- AGIBXHHXWIYYKF-UHFFFAOYSA-N 5,6-dichloro-2,3-dihydro-1H-inden-2-amine Chemical compound ClC1=C(Cl)C=C2CC(N)CC2=C1 AGIBXHHXWIYYKF-UHFFFAOYSA-N 0.000 description 1
- NUXHSMXHQXYDET-UHFFFAOYSA-N 5,6-dichloro-2,3-dihydro-1H-inden-2-ol Chemical compound C1C2=C(CC1O)C=C(Cl)C(Cl)=C2 NUXHSMXHQXYDET-UHFFFAOYSA-N 0.000 description 1
- BVMSVJNZBKHOLJ-UHFFFAOYSA-N 5,6-dichloro-2,3-dihydro-1h-inden-1-ol Chemical compound ClC1=C(Cl)C=C2C(O)CCC2=C1 BVMSVJNZBKHOLJ-UHFFFAOYSA-N 0.000 description 1
- KSTYRFWOQUWBCW-UHFFFAOYSA-N 5,6-dichloro-2,3-dihydroinden-1-one Chemical compound C1=C(Cl)C(Cl)=CC2=C1C(=O)CC2 KSTYRFWOQUWBCW-UHFFFAOYSA-N 0.000 description 1
- OSJRTWXVMCRBKZ-UHFFFAOYSA-N 5,6-difluoro-2,3-dihydroinden-1-one Chemical compound C1=C(F)C(F)=CC2=C1C(=O)CC2 OSJRTWXVMCRBKZ-UHFFFAOYSA-N 0.000 description 1
- BYYGMUGRXMVSNS-UHFFFAOYSA-N 5,6-difluoro-2-hydroxyimino-3h-inden-1-one Chemical compound FC1=C(F)C=C2C(=O)C(=NO)CC2=C1 BYYGMUGRXMVSNS-UHFFFAOYSA-N 0.000 description 1
- XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
- KBMVAIAEDLKXCX-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1h-inden-2-amine Chemical compound C1=C(Cl)C=C2CC(N)CC2=C1 KBMVAIAEDLKXCX-UHFFFAOYSA-N 0.000 description 1
- FXJOTWLLDJYKAG-UHFFFAOYSA-N 5-chloropyrazine-2-carboxylic acid Chemical compound OC(=O)C1=CN=C(Cl)C=N1 FXJOTWLLDJYKAG-UHFFFAOYSA-N 0.000 description 1
- LUYOMLHOURXTCL-UHFFFAOYSA-N 5-ethenylpyrimidin-2-amine Chemical compound NC1=NC=C(C=C)C=N1 LUYOMLHOURXTCL-UHFFFAOYSA-N 0.000 description 1
- PZKFSRWSQOQYNR-UHFFFAOYSA-N 5-methyl-1h-1,2,4-triazole Chemical compound CC1=NC=NN1 PZKFSRWSQOQYNR-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- HLNUJTSDZZJMOW-UHFFFAOYSA-N Cc1ncn(n1)C1CCN(CC1)C(=O)OC(C)(C)C Chemical compound Cc1ncn(n1)C1CCN(CC1)C(=O)OC(C)(C)C HLNUJTSDZZJMOW-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- 108010000659 Choline oxidase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 description 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000031964 Other metabolic disease Diseases 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000995838 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Nucleotide pyrophosphatase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- WGNIPMIDJBODIC-UHFFFAOYSA-N [4-(hydrazinylmethyl)phenyl]methylhydrazine Chemical compound NNCC1=CC=C(CNN)C=C1 WGNIPMIDJBODIC-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- UDLLFLQFQMACJB-UHFFFAOYSA-N azidomethylbenzene Chemical compound [N-]=[N+]=NCC1=CC=CC=C1 UDLLFLQFQMACJB-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 230000037198 cardiovascular physiology Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- AAUBVINEXCCXOK-UHFFFAOYSA-N ethyl 4,6-dichloropyridine-3-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C=C1Cl AAUBVINEXCCXOK-UHFFFAOYSA-N 0.000 description 1
- GHXXCVVSJXZBPO-UHFFFAOYSA-N ethyl 4-cyanobutanoate Chemical compound CCOC(=O)CCCC#N GHXXCVVSJXZBPO-UHFFFAOYSA-N 0.000 description 1
- GVSVPKDEHFOXSW-UHFFFAOYSA-N ethyl 6-chloropyridazine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(Cl)N=N1 GVSVPKDEHFOXSW-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004125 inden-2-yl group Chemical group [H]C1=C(*)C([H])([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- IBMRTYCHDPMBFN-UHFFFAOYSA-N monomethyl glutaric acid Chemical compound COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 description 1
- XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical compound CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- DMEUDSHBHKHLPD-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=C=C[N]1 DMEUDSHBHKHLPD-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ADFSCQGCEAKLOE-UHFFFAOYSA-N tert-butyl 4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate Chemical compound COC(=O)CC1CCN(C(=O)OC(C)(C)C)CC1 ADFSCQGCEAKLOE-UHFFFAOYSA-N 0.000 description 1
- CJVRIMIDHYKFLD-UHFFFAOYSA-N tert-butyl 4-ethynyl-2-methylpiperidine-1-carboxylate Chemical compound CC1CC(CCN1C(=O)OC(C)(C)C)C#C CJVRIMIDHYKFLD-UHFFFAOYSA-N 0.000 description 1
- DVGWDBGQOAGBTF-UHFFFAOYSA-N tert-butyl 4-ethynyl-4-fluoropiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(F)(C#C)CC1 DVGWDBGQOAGBTF-UHFFFAOYSA-N 0.000 description 1
- WOEQSXAIPTXOPY-UHFFFAOYSA-N tert-butyl 4-methylsulfonyloxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)CC1 WOEQSXAIPTXOPY-UHFFFAOYSA-N 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a novel piperidine derivative, and more particularly, to a novel piperidine derivative and a pharmaceutical composition comprising the same for inhibiting autotaxin.
- Autotaxin is a secreted enzyme important for the production of lysophosphatidic acid (LPA), a lipid signaling molecule, and is a member of the ectonucleotide pyrophosphatase/phosphodiesterase family. , ENPP2). Autotaxin exhibits lysophospholipase D activity that converts lysophosphatidylcholine (LPC) to LPA. Thus, LPA levels in plasma and ascites correlate with ATX activity.
- LPA lysophosphatidic acid
- LPC lysophosphatidylcholine
- Plasma LPA is a bioactive lipid that affects the migration, proliferation, and survival of various cell types.
- ATX-LPA signaling process is involved in nervous system function, vascular development, cardiovascular physiology, tissue regeneration, immune system function, chronic inflammation, tumor metastasis and progression, organ fibrosis and obesity and/or other metabolic diseases (e.g., diabetes mellitus). It is involved in the physiological and pathophysiological actions of various diseases, including obesity, diabetes mellitus).
- increased ATX activity and increased LPA levels, altered LPA receptor expression and altered responses to LPA may be associated with the initiation, progression and/or outcome of various pathophysiological diseases associated with the ATX/LPA signaling process.
- various pathophysiological diseases associated with the ATX/LPA signaling process In particular, it is known to be associated with cancer, lymphocyte homing, chronic inflammation, neuropathic pain, fibrotic diseases (eg idiopathic pulmonary fibrosis, IPF), and thrombosis. Accordingly, in order to treat these diseases, it is necessary to lower the level of LPA and/or autotaxin (ATX) that induces it.
- ATX autotaxin
- An object to be solved by the present invention is to provide an autotaxin-inhibiting compound having a novel structure that exhibits excellent inhibitory activity against autotaxin.
- an object to be solved by the present invention is to provide a pharmaceutical composition for inhibiting autotaxin comprising the autotaxin-inhibiting compound having the novel structure.
- an object of the present invention is to provide a method for inhibiting autotaxin and treating and preventing diseases thereof using the novel structure of the autotaxin-inhibiting compound.
- the problem to be solved by the present invention is to provide autotaxin inhibition of the autotaxin-inhibiting compound of the novel structure and the treatment of diseases accordingly.
- a piperidine derivative compound represented by Formula 1 below a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof is provided.
- X is aryl C 1-4 alkyl; a two-ring fused ring in which an aryl ring or a heteroaryl ring having 1 to 3 N atoms and a non-aromatic cycloalkyl ring are fused; Or a two-ring fused ring in which an aryl ring and a non-aromatic heterocyclic ring having 1 to 3 O are fused, X is unsubstituted or substituted with a single or multiple R 1 ,
- A is a 5- or 6-membered heteroaryl having 1 to 3 heteroatoms selected from the group consisting of N, O and S;
- L is C 1-6 alkylene; -(CH 2 ) a CO-; -(CH) a CO-; -(CH 2 ) b O(CH 2 ) c CO-; Or a 5-membered aromatic or non-aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of N and O, wherein a, b, and c are independently integers from 1 to 5,
- B is COOH; CH 2 COOH; CONHOH; SO 2 NH 2 ; a 4- or 5-membered non-aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of N and O; or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from the group consisting of N and O;
- R 1 is halogen or C 1-4 alkylsulfonyl
- R 2 is hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, hydroxy, oxo(O) or aryl C 1-4 alkyl;
- R 3 is hydrogen, C 1-4 alkyl, C 1-4 alkoxy or halogen
- R 4 is hydrogen, halogen or C 1-4 alkyl
- R 5 is hydrogen or C 1-4 alkyl.
- a pharmaceutical composition for preventing or treating diseases associated with autotaxin activity comprising the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. do.
- a method for inhibiting autotaxin and treating or preventing diseases caused by using the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof is provided.
- the use of the piperidine derivative compound, its hydrate, its solvate or its pharmaceutically acceptable salt for inhibiting autotaxin and treating or preventing diseases caused thereby is provided.
- a pharmaceutical composition comprising the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive is provided.
- the piperidine derivative of the novel structure of the present invention is a disease related to autotaxin inhibition, such as fibrotic disease, inflammatory disease, autoimmune disease, respiratory disease, cardiovascular disease, metabolic disease, cancer and cancer metastasis, eye disease, and bile It can be usefully used for the treatment and prevention of chronic pruritus in the stagnant and other forms, and acute or chronic organ transplant rejection.
- autotaxin is a secreted enzyme that plays an important role in the production of lysophosphatidic acid (LPA), ectonucleotide pyrophosphatase / phosphodiesterase 2 (ectonucleotide pyrophosphatase / phosphodiesterase family member 2, also referred to as ENPP2).
- LPA lysophosphatidic acid
- ENPP2 ectonucleotide pyrophosphatase / phosphodiesterase family member 2
- Autotaxin exhibits lysophospholipase D activity that converts lysophosphatidylcholine (LPC) to LPA.
- LPC lysophosphatidylcholine
- the present invention provides a piperidine derivative compound represented by Formula 1 below, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.
- X is aryl C 1-4 alkyl; a two-ring fused ring in which an aryl ring or a heteroaryl ring having 1 to 3 N atoms and a non-aromatic cycloalkyl ring are fused; Or a two-ring fused ring in which an aryl ring and a non-aromatic heterocyclic ring having 1 to 3 O are fused, X is unsubstituted or substituted with a single or multiple R 1 ,
- A is a 5- or 6-membered heteroaryl having 1 to 3 heteroatoms selected from the group consisting of N, O and S;
- L is C 1-6 alkylene; -(CH 2 ) a CO-; -(CH) a CO-; -(CH 2 ) b O(CH 2 ) c CO-; Or a 5-membered aromatic or non-aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of N and O, wherein a, b, and c are independently integers from 1 to 5,
- B is COOH; CH 2 COOH; CONHOH; SO 2 NH 2 ; a 4- or 5-membered non-aromatic heterocycle having 1 to 3 heteroatoms selected from the group consisting of N and O; or a 5-membered heteroaryl having 1 to 4 heteroatoms selected from the group consisting of N and O;
- R 1 is halogen or C 1-4 alkylsulfonyl
- R 2 is hydrogen, C 1-4 alkyl, C 1-4 haloalkyl, hydroxy, oxo(O) or aryl C 1-4 alkyl;
- R 3 is hydrogen, C 1-4 alkyl, C 1-4 alkoxy or halogen
- R 4 is hydrogen, halogen or C 1-4 alkyl
- R 5 is hydrogen or C 1-4 alkyl.
- the X may be one selected from the group consisting of benzyl, phenethyl, dihydroindenyl, dihydrocyclopentapyrazinyl, and benzodioxolyl.
- A may be one selected from the group consisting of pyridine, pyrimidine, pyridazine, pyrazine, oxadiazole, and thiadiazole.
- the L is -(CH 2 ) 3 -, -(CH 2 ) 2 CO-, -(CH 2 ) 3 CO-, -(CH) 2 CO-, -CH 2 OCH 2 CO-, It may be one selected from the group consisting of oxazole, isoxazole, dihydroisoxazole and oxadiazole.
- the B may be one selected from the group consisting of carboxyl, carboxymethyl, carboxamido, sulfonamide, azetidine, morpholine, oxadiazole, imidazole, triazole and tetrazole.
- R 1 may be one selected from the group consisting of F, Cl, Br, and methylsulfonyl.
- R 2 may be one selected from the group consisting of hydrogen, methyl, difluoromethyl, trifluoromethyl, hydroxy, oxo(O), and benzyl.
- R 3 may be one selected from the group consisting of hydrogen, methyl, methoxy, and F.
- R 4 may be one selected from the group consisting of hydrogen, Cl, and methyl.
- R 5 may be hydrogen or alkyl.
- piperidine derivative compounds according to the present invention are as follows:
- alkyl is a straight or branched chain saturated hydrocarbon, preferably C 1 -C 10 alkyl.
- the alkyl is methyl, ethyl, n -propyl, iso -propyl, n -butyl, iso -butyl, tert -butyl, n -pentyl, iso -pentyl, n -hexyl, 3-methylhexyl, 2, 2-dimethylpentyl, 2,3-dimethylpentyl, n -heptyl, n -octyl, n -nonyl and n -decyl, and the like.
- alkylene refers to a divalent functional group derived from an alkyl group, preferably containing, but not limited to, 1 to 10 carbon atoms.
- alkylene include -CH 2 -, -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 - and -CH 2 CH 2 CH 2 CH 2 CH 2 -, etc. This includes, but is not limited to.
- cycloalkyl is a partially or fully saturated mono- or fused-ring cyclic hydrocarbon, with C 3 -C 10 -cycloalkyl being preferred. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexynyl, and the like.
- hydroxy or "hydroxyl” is defined as -OH, and the term “alkoxy”, unless otherwise defined, refers to alkyloxy, a radical in which the hydrogen atoms of a hydroxy group are substituted with 1 to 10 alkyls.
- halogen or “halo” means fluorine/fluorine (F), chlorine (Cl), bromine (Br) or iodine (I).
- heteroatom means N, O or S.
- aryl means an aromatic hydrocarbon and includes polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused with one or more other rings. It is preferably C 5 -C 12 aryl, more preferably C 5 -C 10 aryl.
- the aryl includes, but is not limited to, phenyl, naphthyl, tetrahydronaphthyl, and the like.
- heteroaryl ring is fused to a cycloalkyl or non-aromatic heterocycle ring, such as dihydrocyclopentapyrazinyl.
- heteroaryl or “aromatic heterocycle” refers to a single or fused cyclic ring containing as a reducing agent one or more heteroatoms selected from N, O and S and which may be fused with benzo or C 3 -C 8 cycloalkyl. 3 to 12 membered, more preferably 5 to 10 membered aromatic hydrocarbons.
- the heteroaryl is pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxadiazolyl, isoxadiazolyl, tetrazolyl, indole Lil, indazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, furanyl, benzofuranil, thiophenyl, benzothiazolyl, benzooxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl and the like, but are not limited thereto.
- Arylalkyl, alkylaryl, and heteroarylalkyl refer to groups formed by combining the above-defined aryl and alkyl or heteroaryl and alkyl, and include, for example, benzyl, phenethyl, etc., but are not limited thereto.
- the compound represented by Formula 1 can be used in the form of a prodrug, hydrate, solvate, or pharmaceutically acceptable salt in order to enhance absorption or solubility in vivo, the prodrug, Hydrates, solvates and pharmaceutically acceptable salts are also within the scope of this invention.
- the compound represented by Formula 1 has a chiral carbon, stereoisomers thereof exist, and these stereoisomers are also included within the scope of the present invention.
- prodrug refers to a substance that is transformed into the parent drug in vivo. Prodrugs are often used because, in some cases, they are easier to administer than the parent drug. For example, they may obtain bioactivity by oral administration whereas the parent agent may not. A prodrug may also have improved solubility in a pharmaceutical composition than the parent drug.
- a prodrug may be an in vivo hydrolyzable ester of a compound according to the present invention and a pharmaceutically acceptable salt thereof.
- Another example of a prodrug would be a short peptide (polyamino acid) attached to an acid group that is metabolized to reveal an active site.
- hydrate refers to a compound of the present invention that contains a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. or a salt thereof.
- solvate refers to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces.
- Preferred solvents in this regard are those that are volatile, non-toxic, and/or suitable for administration to humans.
- isomers refers to compounds of the present invention or salts thereof that have the same chemical formula or molecular formula but differ structurally or sterically. These isomers include both structural isomers such as tautomers, R or S isomers having an asymmetric carbon center, and stereoisomers such as geometric isomers (trans, cis). All these isomers and mixtures thereof are also included within the scope of the present invention.
- pharmaceutically acceptable salt refers to a salt form of a compound that does not cause significant irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound.
- the pharmaceutical salt is an acid that forms a non-toxic acid addition salt containing a pharmaceutically acceptable anion, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, tartaric acid, and formic acid.
- organic carbonic acids such as citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. Acid addition salts formed with the same sulfonic acids and the like are included.
- carboxylic acid salts include metal salts or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium, etc., amino acid salts such as lysine, arginine, guanidine, dicyclohexylamine, N- organic salts such as methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline and triethylamine; and the like.
- the compound of Formula 1 according to the present invention may be converted into a salt thereof by a conventional method.
- the present invention provides a method for preparing the compound of Formula 1.
- Reaction Schemes 1 to 26 are exemplified as a method for preparing the compound of Formula 1 of the present invention, and the following preparation method does not limit the method for preparing the compound of Formula 1 according to the present invention.
- the preparation methods of Reaction Schemes 1 to 26 below are only examples, and it is obvious that they can be easily modified by a person skilled in the art according to specific substituents.
- the present invention also provides a pharmaceutical composition for preventing or treating diseases related to autotaxin activity, comprising the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the present invention also provides a method for administering the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof to a patient in need thereof, thereby inhibiting autotaxin and treating or preventing diseases caused thereby. provides a way
- the present invention also provides a use of the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof for inhibiting autotaxin and treating or preventing diseases accordingly.
- the disease associated with autotaxin activity is fibrotic disease, inflammatory disease, autoimmune disease, respiratory disease, cardiovascular disease, metabolic disease, cancer and cancer metastasis, ocular disease, cholestasis and other forms of chronic pruritus. , and may be selected from the group consisting of acute or chronic organ transplant rejection.
- the fibrotic disease includes, but is not limited to, idiopathic pulmonary fibrosis (IPF), interstitial lung disease, liver fibrosis, liver cirrhosis, non-alcoholic steatohepatitis, radiation-induced fibrosis, myocardial and vascular fibrosis, renal fibrosis, skin fibrosis, glomerular sclerosis, myocardial and vascular fibrosis.
- IPF idiopathic pulmonary fibrosis
- interstitial lung disease fibrosis
- liver fibrosis liver fibrosis
- liver cirrhosis liver cirrhosis
- non-alcoholic steatohepatitis non-alcoholic steatohepatitis
- radiation-induced fibrosis myocardial and vascular fibrosis
- renal fibrosis renal fibrosis
- skin fibrosis skin fibrosis
- glomerular sclerosis myocardial and vascular fibrosis.
- the inflammatory disease includes, but is not limited to, rheumatoid arthritis, osteoarthritis, atopic dermatitis, inflammatory bowel disease, inflammatory airway disease, chronic obstructive pulmonary disease (COPD) and asthma.
- COPD chronic obstructive pulmonary disease
- Such autoimmune diseases include, but are not limited to, multiple sclerosis and scleroderma.
- the respiratory disease includes, but is not limited to, asbestos-induced pulmonary fibrosis and acute respiratory distress syndrome (ARDS).
- ARDS acute respiratory distress syndrome
- the cardiovascular disease includes, but is not limited to, atherosclerosis, myocardial infarction, arterial and pulmonary hypertension, cardiac arrhythmia, stroke and other vascular damage.
- the metabolic disease includes, but is not limited to, obesity and diabetes.
- the cancer and cancer metastasis include, but are not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, hepatocarcinoma, gastrointestinal cancer, pancreatic cancer, and their progression and metastatic invasion.
- Such eye diseases include, but are not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), macular edema, central artery/venous occlusion, traumatic injury, and glaucoma.
- proliferative and non-proliferative (diabetic) retinopathy dry and wet age-related macular degeneration (AMD), macular edema, central artery/venous occlusion, traumatic injury, and glaucoma.
- AMD age-related macular degeneration
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising the piperidine derivative compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive.
- the additives may include pharmaceutically acceptable carriers or diluents, and oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterilization according to conventional methods, respectively. It can be formulated in the form of an injection solution.
- the pharmaceutically acceptable carrier is lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil; and the like.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants are included.
- Solid preparations for oral use include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one or more excipients, for example, starch, calcium carbonate, sucrose or lactose. ), gelatin, and the like, and may include lubricants such as magnesium stearate and talc.
- Oral liquid preparations include suspensions, internal solutions, emulsions, syrups, and the like, and may include diluents such as water and liquid paraffin, wetting agents, sweeteners, aromatics, and preservatives.
- Parenteral formulations include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, creams, lyophilized formulations, and suppositories
- non-aqueous solvents and suspensions include vegetable oils, injectable esters such as ethyl oleate, and the like.
- suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- the dose of the active ingredient contained in the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the type of active ingredient, the route and period of administration, and may be appropriately adjusted according to the patient.
- the active ingredient may be administered at a dose of 0.0001 to 1000 mg/kg per day, preferably 0.01 to 100 mg/kg, and the administration may be administered once or several times a day.
- the pharmaceutical composition of the present invention may include the active ingredient in a weight percentage of 0.001 to 90% based on the total weight of the composition.
- the pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes, for example, oral, dermal, abdominal, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular. It may be administered by injection.
- Step 1 Preparation of tert -butyl 4-(1 H -1,2,3-triazol-5-yl)piperidine-1-carboxylate (2) : tert- Butyl 4-ethynylpiperidine-1-carboxylate ( 1 , 1.05 g, 5.00 mmol), trimethylsilyl azide (5.5 mmol) and copper(I) iodide (0.25 mmol) were dissolved under argon gas with N ,N-dimethylformamide/methanol (9:1, 2 mL) was added to the mixture. The reaction mixture was heated at 100 °C for 12 hours under argon gas.
- Step 2 Preparation of 4-(1H - 1,2,3-triazol-5-yl)piperidine.HCl (3) : tert -butyl 4-( 1H- 1,2 obtained from step above) To a solution of ,3-triazol-5-yl)piperidine-1-carboxylate (3.60 mmol) in dioxane (10 mL) was added 4.0 M hydrogen chloride solution (dioxane (2 mL)). The reaction mixture was stirred overnight at room temperature. Evaporation of the solvent to dryness gave the title compound as a white solid (quantitatively).
- Step 1 tert-butyl 4-(1H-1,2,4-triazol-1-yl)piperidine-1-carboxylate (Im15-1a) and tert -Butyl 4-(3-methyl-1 H Preparation of -1,2,4-triazol-1-yl)piperidine-1-carboxylate (Im15-1b)
- 1,2,4-triazole or 3-methyl-1,2,4-triazole (1 mmol) and sodium hydride (1.3 mmol) were dissolved in 5 mL of DMF and stirred at 0 °C for 1 hour.
- 4-[(methylsulfonyl)oxy]piperidine-1-carboxylic acid tert-butyl ester (1.1 mmol) was added to the reaction mixture under argon gas.
- the reaction mixture was heated at 90 °C for 5 hours.
- the solvent was evaporated to dryness, extracted with ethyl acetate and washed with brine.
- the organic layer was dried over anhydrous sodium sulfate and concentrated.
- the product was purified by column chromatography (EA/Hex) to give the title compound as a white solid.
- Step 2 4-(1H-1,2,4-triazol-1-yl)piperidine HCl (Im15-2a) and 4-(3-methyl-1H-1,2,4-triazole- Preparation of 1-day) piperidine HCl (Im15-2b)
- 3,4-Difluorophenyl propionic acid (925.8 mg, 4.97 mmol) was dissolved in DCM (20 mL). Oxalyl chloride (9.94 mmol) and 1 drop of DMF were added to the reaction mixture. The resulting solution was stirred for 3-5 hours. After completion of the reaction, the solvent was removed under vacuum. 3-(3,4-difluorophenyl)propanoyl chloride was then dissolved in DCM and added slowly to AlCl 3 (17.4 mmol) in DCM at 0 °C. The reaction mixture was stirred at 0 °C for 15 minutes and refluxed for 4 hours.
- Step 1 tert-Butyl 4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate [tert-butyl 4-(5- Preparation of (difluoromethyl)-1,3,4-oxadiazol-2-yl)piperidine-1-carboxylate] (im20-1)
- Step 2 2-(difluoromethyl)-5-(piperidin-4-yl)-1,3,4-oxadiazole [2-(difluoromethyl)-5-(piperidin-4-yl)- Preparation of 1,3,4-oxadiazole] (im20)
- Step 1 tert-butyl 3-(prop-1-yn-1-yl)piperidine-1-carboxylate [tert-butyl 4-(prop-1-yn-1-yl)piperidine-1-carboxylate ] (im21-1) Preparation
- Step 2 tert-butyl 4-(4-methyl-1H-1,2,3-triazol-5-yl)piperidine-1-carboxylate [tert-butyl 4-(4-methyl-1H- Preparation of 1,2,3-triazol-5-yl)piperidine-1-carboxylate] (im21-2)
- Step 1 Ethyl 2-((2,3-dihydro- 1H Preparation of -inden-2-yl)amino)pyrimidine-5-carboxylate (5a)
- Step 3 5-(2-((2,3-dihydro-1 H Preparation of -inden-2-yl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2(3H)-one (7a)
- Step 4 5-(5-(4-(1 H -1,2,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl)- N -(2,3-dihydro-1 H -Inden-2-yl)pyrimidin-2-amine [5-(5-(4-(1) H -1,2,3-triazol-5-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl)- N -(2,3-dihydro-1 H -inden-2-yl) pyrimidin-2-amine] (8a)
- Example 1 except that 5-chloro-2,3-dihydro- 1H -inden-2-amine ( 4c ) was used instead of 2,3-dihydro- 1H -inden-2-amine ( 4a ).
- the title compound was prepared in the same manner as in (yield: 62.5%).
- Example 8 6-(5-(4-(1) H -1,2,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl)- N -(2,3-dihydro-1 H -Inden-2-yl)pyridazin-3-amine [6-(5-(4-(1) H -1,2,3-triazol-5-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl)- N -(2,3-dihydro-1 H -inden-2-yl) pyridazin-3-amine] (14)
- Step 1-1 tert -Butyl 2-methyl-4-(1 H Preparation of -1,2,3-triazol-5-yl)piperidine-1-carboxylate (M2)
- Step 1-2 Preparation of 2-methyl-4-(1H-1,2,3-triazol-5-yl)piperidine HCl (M3)
- Step 2 N -(5-bromo-2,3-dihydro-1 H -Inden-2-yl)-5-(5-(2-methyl-4-(1) H -1,2,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl) pyrimidin-2-amine [ N -(5-bromo-2,3-dihydro-1 H -inden-2-yl)-5-(5-(2-methyl-4-(1 H -1,2,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl) pyrimidin-2-amine] (16)
- Step 2 Ethyl 6-((5-bromo-2,3-dihydro-1 H Preparation of -inden-2-yl) amino) nicotinate (A5a)
- Step 3 6-((5-bromo-2,3-dihydro-1 H Preparation of -inden-2-yl) amino) nicotinohydrazide (A6a)
- Step 4 5-(6-((5-bromo-2,3-dihydro-1 H -inden-2-yl) amino) pyridin-3-yl) -1,3,4-oxadiazole-2 (3 H ) Preparation of one (A7a)
- Step 5 5-(5-(4-(1) H -1,2,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl)- N -(5-bromo-2,3-dihydro-1 H -inden-2-yl)pyridin-2-amine [5-(5-(4-(1) H -1,2,3-Triazol-5-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl)- N -(5-bromo-2,3-dihydro-1 H -inden-2-yl) pyridin-2-amine] (17a)
- Step 1 Ethyl 6-((5-bromo-2,3-dihydro-1 H Preparation of -inden-2-yl)amino)-4-chloronicotinate (A5c)
- Step 2 6-((5-Bromo-2,3-dihydro-1 H Preparation of -inden-2-yl)amino)-4-chloronicotinic acid (A6c)
- Step 3 5-(6-((5-bromo-2,3-dihydro-1 H Preparation of -inden-2-yl) amino) -4-chloropyridin-3-yl) -1,3,4-oxadiazol-2 (3H) -yl (A7c)
- Step 4 5-(5-(4-(1 H -1,2,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl)- N -(5-bromo-2,3-dihydro-1 H -Inden-2-yl)-4-chloropyridin-2-amine [5-(5-(4-(1 H -1,2,3-Triazol-5-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl)- N -(5-bromo-2,3-dihydro-1 H -inden-2-yl) -4-chloropyridin-2-amine] (18)
- Example 17 1-(4-(1H-1,2,3-triazol-5-yl)piperidin-1-yl)-3-(2-((2,3-dihydro-1 H -inden-2-yl)amino)pyrimidin-5-yl)propan-1-one [1-(4-(1H-1,2,3-triazol-5-yl)piperidin-1-yl)-3 -(2-((2,3-dihydro-1 H -inden-2-yl) amino) pyrimidin-5-yl) propan-1-one] (20a)
- Step 1 Preparation of ( E )-ethyl 3-(2-chloropyrimidin-5-yl)acrylate (imL14-1): 5-bromo-2-chloropyrimidine (0.19 g, 1.00 mmol), ethyl Acrylate (0.42 mL, 4.00 mmol), palladium(II) diacetate (8.98 mg, 0.04 mmol), tri( o -tolyl)phosphine (30.43 mg, 0.10 mmol) in dimethylformamide (2 mL) and diiso The mixture in propylethylamine (1 mL) was heated at reflux for 4 hours and then cooled to room temperature.
- Step 2 ( E )-ethyl 3-(2-((2,3-dihydro-1 H Preparation of -inden-2-yl)amino)pyrimidin-5-yl)acrylate (imL14-2)
- Step 3 Ethyl 3-(2-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) pyrimidin-5-yl) propanoate (imL14-3)
- Step 4 3-(2-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) pyrimidin-5-yl) propanoic acid (L14)
- Step 5 1-(4-(1H-1,2,3-triazol-5-yl)piperidin-1-yl)-3-(2-((2,3-dihydro-1 H -inden-2-yl)amino)pyrimidin-5-yl)propan-1-one [1-(4-(1H-1,2,3-triazol-5-yl)piperidin-1-yl)-3 -(2-((2,3-dihydro-1 H -inden-2-yl) amino) pyrimidin-5-yl) propan-1-one] (20a)
- Example 18 1-(4-(1 H -imidazol-5-yl)piperidin-1-yl)-3-(2-((2,3-dihydro-1 H -inden-2-yl)amino)pyrimidin-5-yl)propan-1-one [1-(4-(1 H -imidazol-5-yl)piperidin-1-yl)-3-(2-((2,3-dihydro-1 H -inden-2-yl) amino) pyrimidin-5-yl) propan-1-one] (20b)
- Step 1 2-isothiocyanato-2,3-dihydro-1 H -Preparation of indene (imL15-1)
- Step 2 N -(2,3-dihydro-1 H Preparation of -inden-2-yl)hydrazinecarbothioamide (imL15-2)
- Step 3 Ethyl 4-(5-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) -1,3,4-thiadiazol-2-yl) butanoate (imL15-3)
- Step 4 4-(5-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) -1,3,4-thiadiazol-2-yl) butanoic acid (L15)
- Step 5 1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl)amino)-1,3,4-thiadiazol-2-yl)butan-1-one [1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl) amino) -1,3,4-thiadiazol-2-yl) butan-1-one] (21a)
- Example 20 1-(4-(1H-imidazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1H-indene - 2- yl)amino)-1,3,4-thiadiazol-2-yl)butan-1-one [1-(4-(1H-imidazol-5-yl)piperidin-1-yl)-4-(5 Preparation of ((2,3-dihydro-1H-inden-2-yl)amino)-1,3,4-thiadiazol-2-yl)butan-1-one] (21b): Step 5 of Example 19 4-( 1H - imidazol -5-yl)piperidine (18.14 mg, The title compound was obtained as a white solid (38.24 mg, 68.0%) in the same manner except that 0.12 mmol) was used.
- Example 21 1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl)amino)-1,3,4-oxadiazol-2-yl)butan-1-one [1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl) amino) -1,3,4-oxadiazol-2-yl) butan-1-one] (22a)
- Step 1 tert -Preparation of butyl 2-(5-methoxy-5-oxopentanoyl)hydrazinecarboxylate (imL17-1)
- Step 2 Preparation of methyl 5-hydrazinyl-5-oxopentanoate hydrochloride (imL17-2)
- Step 3 Preparation of methyl 4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)butanoate (imL17-3)
- Step 4 Methyl 4-(5-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) -1,3,4-oxadiazol-2-yl) butanoate (imL17-4)
- Step 5 4-(5-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) -1,3,4-oxadiazol-2-yl) butanoic acid (L17)
- the title compound was obtained as a white solid (0.11 g, 96.8%) in the same manner as in Example 17, step 4, except that imL17-4 (0.12 g, 0.40 mmol) was used instead of imL14-3 .
- Step 6 1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl)amino)-1,3,4-oxadiazol-2-yl)butan-1-one [1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl) amino) -1,3,4-oxadiazol-2-yl) butan-1-one] (22a)
- Example 22 1-(4-(1H-imidazol-5-yl)piperidin-1-yl)-4-(5-((2,3-dihydro-1 H -inden-2-yl)amino)-1,3,4-oxadiazol-2-yl)butan-1-one [1-(4-(1H-imidazol-5-yl)piperidin-1-yl) Preparation of -4-(5-((2,3-dihydro-1H-inden-2-yl)amino)-1,3,4-oxadiazol-2-yl)butan-1-one] (22b)
- Step 2 Methyl 2-((5-((2,3-dihydro-1 H Preparation of -inden-2-yl) amino) -1,3,4-thiadiazol-2-yl) methoxy) acetate (imL18-2)
- Step 3 2-((5-((2,3-dihydro-1 H Preparation of -inden-2-yl)amino)-1,3,4-thiadiazol-2-yl)methoxy)acetic acid (L18)
- Step 4 1-(4-(1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-2-((5-((2,3-dihydro-1 H -inden-2-yl) amino) -1,3,4-thiadiazol-2-yl) methoxy) ethanone [1- (4- (1 H -1,2,3-triazol-5-yl)piperidin-1-yl)-2-((5-((2,3-dihydro-1 H -inden-2-yl) amino) -1,3,4-thiadiazol-2-yl) methoxy) ethanone] (23)
- Step 1 Ethyl (E)-3-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)acrylate [ Preparation of ethyl (E)-3-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)acrylate] (imL22-1)
- Step 2 (E)-3-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)acrylic acid [(E Preparation of )-3-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)acrylic acid] (L22)
- the title compound was obtained as a pale yellow solid (0.90 g, 97.0%) by the same method as in Example 17, step 4, using imL22-1 instead of imL14-3 .
- Step 3 (E)-1-(4-(1H-1,2,3-Triazol-5-yl)piperidin-1-yl)-3-(2-((5,6-difluoro) Rho-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)prop-2-en-1-one [(E)-1-(4-(1H-1 ,2,3-triazol-5-yl)piperidin-1-yl)-3-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5 -yl) prop-2-en-1-one] (30)
- Step 1-1 4-ethynylpiperidine hydrochloride Preparation of (imL23-1)
- tert-Butyl 4-ethynylpiperidine-1-carboxylate (12.0 g, 57.4 mmol) was dissolved in Et 2 O (100 mL) and cooled to 0 °C. HCl in Et 2 O (4 M, 100 mL) was added and the mixture was stirred for 20 h. Et 2 O was evaporated, PE was added, and the solid was filtered and washed with PE and Et 2 O to obtain the titled compound ( imL23-1 ) as a white solid (8.3 g, yield: 99.4%).
- Step 1-2 tert-butyl (2-(4-ethynylpiperidin-1-yl)-2-oxoethyl)carbamate [tert-butyl (2-(4-ethynylpiperidin-1-yl)-2- oxoethyl)carbamate] (imL23-2) Preparation
- Step 1-3 2-amino-1- (4-ethynylpiperidin-1-yl) ethanone hydrochloride [2-amino-1- (4-ethynylpiperidin-1-yl) ethanone hydrochloride] (imL23-3 ) manufacture of
- Step 2-2 2-chloro-N-(2-(4-ethynylpiperidin-1-yl)-2-oxoethyl)pyrimidine-5-carboxamide [2-chloro-N-(2- Preparation of (4-ethynylpiperidin-1-yl)-2-oxoethyl)pyrimidine-5-carboxamide] (imL23-5)
- Step 2-3 2-(2-chloropyrimidin-5-yl)-5-(4-ethynylpiperidin-1-yl)oxazole [2-(2-chloropyrimidin-5-yl)-5- Preparation of (4-ethynylpiperidin-1-yl)oxazole] (imL23-6)
- Step 2-4 N-(2,3-dihydro-1H-inden-2-yl)-5-(5-(4-ethynylpiperidin-1-yl)oxazol-2-yl)pyrimidine -2-amine [N-(2,3-dihydro-1H-inden-2-yl)-5-(5-(4-ethynylpiperidin-1-yl)oxazol-2-yl)pyrimidin-2-amine] ( Preparation of L23)
- Step 2-5 5-(5-(4-(1-benzyl-1H-1,2,3-triazol-5-yl)piperidin-1-yl)oxazol-2-yl)-N -(2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine [5-(5-(4-(1-benzyl-1H-1,2,3-triazol-5-yl) Preparation of )piperidin-1-yl)oxazol-2-yl)-N-(2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine] (31)
- Step 1 5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)(methyl)amino)pyrimidin-5-yl)-1,3, 4-oxadiazol-2(3H)-one [5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)(methyl)amino)pyrimidin-5-yl Preparation of )-1,3,4-oxadiazol-2(3H)-one] (L26)
- Step 2 5-(5-(4-(1H-1,2,3-triazol-5-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl) -N-(5,6-difluoro-2,3-dihydro-1H-inden-2-yl)-N-methylpyrimidin-2-amine [5-(5-(4-(1H-1 ,2,3-triazol-5-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl)-N-(5,6-difluoro-2,3-dihydro-1H-inden- Preparation of 2-yl) -N-methylpyrimidin-2-amine] (32)
- Step 1-1 Preparation of azidomethyl pivalate (im27-1)
- Step 1-2 tert-Butyl 4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate [tert- Preparation of butyl 4-(1-((pivaloyloxy)methyl)-1H-1,2,3-triazol-4-yl)piperidine-1-carboxylate] (im27-2)
- Step 1-3 (4-(piperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl pivalate trifluoroacetic acid salt [(4-(piperidin-4- Preparation of yl) -1H-1,2,3-triazol-1-yl) methyl pivalate trifluoroacetic acid salt] (im27)
- Step 2-1 (4-(1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl )-1,3,4-oxadiazol-2-yl)piperidin-4-yl)-1H-1,2,3-triazol-1-yl)methyl pivalate [(4-(1- (5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)piperidin -4-yl) -1H-1,2,3-triazol-1-yl) methyl pivalate] (L27)
- Step 2-2 N-(5,6-difluoro-2,3-dihydro-1H-inden-2-yl)-5-(5-(4-(1-methyl-1H-1,2 ,3-triazol-5-yl) piperidin-1-yl) -1,3,4-oxadiazol-2-yl) pyrimidin-2-amine [N- (5,6-difluoro-2 ,3-dihydro-1H-inden-2-yl)-5-(5-(4-(1-methyl-1H-1,2,3-triazol-5-yl)piperidin-1-yl)-1, 3,4-oxadiazol-2-yl) pyrimidin-2-amine] (33)
- Step 1 N-(5,6-difluoro-2,3-dihydro-1H-inden-2-yl)-5-(5-(4-ethynylpiperidin-1-yl)-1, 3,4-oxadiazol-2-yl)pyrimidin-2-amine [N-(5,6-difluoro-2,3-dihydro-1H-inden-2-yl)-5-(5-(4 Preparation of -ethynylpiperidin-1-yl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine] (L28)
- Step 2 N-(5,6-difluoro-2,3-dihydro-1H-inden-2-yl)-5-(5-(4-(1-methyl-1H-1,2,3 -triazol-4-yl)piperidin-1-yl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine [N-(5,6-difluoro-2,3 -dihydro-1H-inden-2-yl)-5-(5-(4-(1-methyl-1H-1,2,3-triazol-4-yl)piperidin-1-yl)-1,3, Preparation of 4-oxadiazol-2-yl) pyrimidin-2-amine] (34)
- Step 1 N-(2,3-dihydro-1H-inden-2-yl)-5-vinylpyrimidin-2-amine [N-(2,3-dihydro-1H-inden-2-yl)- Preparation of 5-vinylpyrimidin-2-amine] (imL24-1)
- Step 2 5-(3-Bromo-4,5-dihydroisoxazol-5-yl)-N-(2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine [ Preparation of 5-(3-bromo-4,5-dihydroisoxazol-5-yl)-N-(2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine] (L24)
- Step 3 N-indan-2-yl-5-[3-[4-(1H-triazol-5-yl)-1-piperidyl]-4,5-dihydroisoxazol-5-yl] Pyrimidine-2-amine [N-indan-2-yl-5-[3-[4-(1H-triazol-5-yl)-1-piperidyl]-4,5-dihydroisoxazol-5-yl]pyrimidin- Preparation of 2-amine] (35)
- Example 40 5-(3-(4-(1H-1,2,3-triazol-5-yl)piperidin-1-yl)isoxazol-5-yl)-N-(5 -Fluoro-2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine [ 5-(3-(4-(1H-1,2,3-triazol-5-yl)piperidin -1-yl) isoxazol-5-yl) -N- (5-fluoro-2,3-dihydro-1H-inden-2-yl) pyrimidin-2-amine]
- Example 50 5-(3-(4-(1H-tetrazol-5-yl)piperidin-1-yl)-4,5-dihydroisoxazol-5-yl)-N-(2 ,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine [ 5-(3-(4-(1H-tetrazol-5-yl)piperidin-1-yl)-4,5-dihydroisoxazol -5-yl) -N- (2,3-dihydro-1H-inden-2-yl) pyrimidin-2-amine]
- Step 1 5-(3-(4-(1H-tetrazol-5-yl)piperidin-1-yl)-4,5-dihydroisoxazol-5-yl)-N-(5-fluoro Rho-2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine [5-(3-(4-(1H-tetrazol-5-yl)piperidin-1-yl)-4; Preparation of 5-dihydroisoxazol-5-yl)-N-(5-fluoro-2,3-dihydro-1H-inden-2-yl)pyrimidin-2-amine]
- Step 2 N-(5-fluoro-2,3-dihydro-1H-inden-2-yl)-5-(3-(4-(5-(trifluoromethyl)-1,3,4 -Oxadiazol-2-yl)piperidin-1-yl)-4,5-dihydroisooxazol-5-yl)pyrimidin-2-amine
- N-(5-fluoro-2,3-dihydro -1H-inden-2-yl)-5-(3-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)piperidin-1-yl)-4,5-dihydroisoxazol- Preparation of 5-yl) pyrimidin-2-amine
- Example 64 1-(1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl) -1,3,4-oxadiazol-2-yl)piperidin-4-yl)azetidin-3-ol [1-(1-(5-(2-((5,6-difluoro-2 ,3-dihydro-1H-inden-2-yl) amino) pyrimidin-5-yl) -1,3,4-oxadiazol-2-yl) piperidin-4-yl) azetidin-3-ol]
- Example 65 1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)-1, 3,4-oxadiazol-2-yl)piperidine-4-sulfonamide [1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl Preparation of )amino)pyrimidin-5-yl)-1,3,4-oxadiazol-2-yl)piperidine-4-sulfonamide]
- Step 2 Methyl 1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)-1,3 ,4-oxadiazol-2-yl)piperidine-4-carboxylate [methyl 1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2- Preparation of yl) amino) pyrimidin-5-yl) -1,3,4-oxadiazol-2-yl) piperidine-4-carboxylate] (L29)
- Step 3 1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl)amino)pyrimidin-5-yl)-1,3, 4-oxadiazol-2-yl)piperidine-4-carboxylic acid [1-(5-(2-((5,6-difluoro-2,3-dihydro-1H-inden-2-yl) Preparation of amino) pyrimidin-5-yl) -1,3,4-oxadiazol-2-yl) piperidine-4-carboxylic acid] (67)
- N-(5,6-difluoro-2,3-dihydro-1H-inden-2-yl)-5-(5-(4-ethynyl- 4-fluoropiperidin-1-yl)-1,3,4-oxadiazol-2-yl)pyrimidin-2-amine] (L31) was prepared (55 mg, yield: 83%).
- a solution of each synthesized compound (80 uM, 100% dimethyl sulfoxide) was diluted 5-fold in turn using dimethyl sulfoxide to prepare 6 concentrations.
- Compounds at each concentration were diluted in duplicate with 1x test buffer (50 mM Tris-Cl (pH 8.0), 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 140 mM NaCl, 3-distilled water, 1 mg/mL BSA). After dilution, 1 uL (1.25% dimethyl sulfoxide) was dispensed into a 96 well clear round bottom plate.
- Example number Inhibition rate (%) at 500 nM Example number Inhibition rate (%) at 500 nM
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
실시예 번호 | 억제율(%) at 500nM | 실시예 번호 | 억제율(%) at 500nM |
1 | 99 | 37 | 93.2 |
2 | 100 | 38 | 53.2 |
3 | 100 | 39 | 97.2 |
4 | 90 | 40 | 68.5 |
5 | 100 | 41 | 40.6 |
6 | 91 | 42 | 8.6 |
7 | 40 | 43 | 4.6 |
8 | 14 | 44 | 71.3 |
9 | 81 | 45 | 1.6 |
10 | 75 | 46 | 1 |
11 | 99 | 47 | 29.2 |
12 | 84 | 48 | 3.4 |
13 | 75 | 49 | 1.2 |
14 | 5 | 50 | 7 |
15 | 100 | 51 | 13.2 |
16 | 84 | 52 | 4.8 |
17 | 92 | 53 | 10.2 |
18 | 85 | 54 | 95.3 |
19 | 43 | 55 | 52 |
20 | 14 | 56 | 55.8 |
21 | 64 | 57 | 88.1 |
22 | 17 | 58 | 84 |
23 | 20 | 59 | 98.5 |
24 | 30.2 | 60 | 95.3 |
25 | 31.1 | 61 | 70 |
26 | 27.9 | 62 | 70.2 |
27 | 29 | 63 | 42.9 |
28 | 52.5 | 64 | 28.1 |
29 | 90.8 | 65 | 58 |
30 | 97.8 | 66 | 86.8 |
31 | 8.1 | 67 | 30.9 |
32 | 34.3 | 68 | 87.1 |
33 | 78.4 | 69 | 66.8 |
34 | 17.3 | 70 | 97.9 |
35 | 96 | 71 | 98.6 |
36 | 53.4 |
Claims (16)
- 하기 화학식 1로 표시되는 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염:<화학식 1>상기 식에서,X는 아릴 C1-4알킬; 아릴 고리 또는 1 내지 3개의 N을 갖는 헤테로아릴 고리와 비방향족 사이클로알킬 고리가 융합된 2개환의 융합고리; 또는 아릴 고리와 1 내지 3개의 O를 갖는 비방향족 헤테로사이클 고리가 융합된 2개환의 융합고리이고, X는 단수 또는 복수의 R1으로 치환되거나 치환되지 않고,A는 N, O 및 S로 구성되는 군으로부터 선택되는 1개 내지 3개의 헤테로원자를 갖는 5원환 또는 6원환의 헤테로아릴이고,L은 C1-6 알킬렌; -(CH2)aCO-; -(CH)aCO-; -(CH2)bO(CH2)cCO-; 또는 N 및 O로 구성되는 군으로부터 선택되는 1개 내지 3개의 헤테로원자를 갖는 5원환의 방향족 또는 비방향족의 헤테로사이클이고, 상기 a, b, c는 독립적으로 1 내지 5의 정수이고,B는 COOH; CH2COOH; CONHOH; SO2NH2; N 및 O로 구성되는 군으로부터 선택되는 1개 내지 3개의 헤테로원자를 갖는 4원환 또는 5원환의 비방향족 헤테로사이클; 또는 N 및 O로 구성되는 군으로부터 선택되는 1개 내지 4개의 헤테로원자를 갖는 5원환의 헤테로아릴이고,R1은 할로겐 또는 C1-4 알킬설포닐이고,R2는 수소, C1-4 알킬, C1-4 할로알킬, 히드록시, 옥소(O) 또는 아릴 C1-4알킬이고,R3는 수소, C1-4 알킬, C1-4 알콕시 또는 할로겐이고,R4는 수소, 할로겐 또는 C1-4 알킬이고,R5는 수소 또는 C1-4 알킬이다.
- 제1항에 있어서, 상기 X가 벤질, 펜에틸, 디하이드로인데닐, 디하이드로시클로펜타피라지닐 및 벤조다이옥솔릴로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 A가 피리딘, 피리미딘, 피리다진, 피라진, 옥사디아졸 및 티아디아졸로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 L이 -(CH2)3-, -(CH2)2CO-, -(CH2)3CO-, -(CH)2CO-, -CH2OCH2CO-, 옥사졸, 이소옥사졸, 디하이드로이소옥사졸 및 옥사디아졸로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 B가 카르복실, 카르복시메틸, 카르복사미도, 설폰아미드, 아제티딘, 모폴린, 옥사디아졸, 이미다졸, 트리아졸 및 테트라졸로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 R1이 F, Cl, Br 및 메틸설포닐로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 R2가 수소, 메틸, 디플루오로메틸, 트리플루오로메틸, 히드록시, 옥소(O) 및 벤질로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 R3가 수소, 메틸, 메톡시 및 F로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 R4가 수소, Cl 및 메틸로 이루어진 군으로부터 선택된 하나인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 R5가 수소 또는 알킬인 것을 특징으로 하는, 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서, 상기 피페리딘 유도체 화합물은[1] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(2,3- 디하이드로-1H-인덴-2-일)피리미딘-2-아민,[2] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[3] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-클로로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[4] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-브로모-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[5] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[6] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-디클로로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[7] N-(5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-일)-6,7-디하이드로-5H-시클로펜타[b]피라진-6-아민,[8] 6-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(2,3-디하이드로-1H-인덴-2-일)피리다진-3-아민,[9] 5-(5-(4-(1H-1,2,4-트리아졸-1-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(2,3-디하이드로-1H-인덴-2-일) 피리미딘-2-아민,[10] N-(2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-(3-메틸-1H-1,2,4-트리아졸-1-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[11] N-(5-브로모-2,3-디하이드로-1H-인덴-2-일)-5-(5-(2-메틸-4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[12] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-브로모- 2,3-디하이드로-1H-인덴-2-일)피리딘-2-아민,[13] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-브로모-2,3-디하이드로-1H-인덴-2-일)피라진-2-아민,[14] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-브로모-2,3-디하이드로-1H-인덴-2-일)-4-클로로피리딘-2-아민,[15] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(3,5-디클로로벤질)피리미딘-2-아민,[16] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(3,5-디클로로펜에틸)피리미딘-2-아민,[17] 1-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-3-(2-((2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)프로판-1-온,[18] 1-(4-(1H-이미다졸-5-일)피페리딘-1-일)-3-(2-((2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일) 프로판-1-온,[19] 1-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4-(5-((2,3-디하이드로-1H-인덴-2-일)아미노)-1,3,4-티아디아졸-2-일)부탄-1-온,[20] 1-(4-(1H-이미다졸-5-일)피페리딘-1-일)-4-(5-((2,3-디하이드로-1H-인덴-2-일)아미노)-1,3,4-티아디아졸-2-일)부탄-1-온,[21] 1-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4-(5-((2,3-디하이드로-1H-인덴-2-일)아미노)-1,3,4-옥사디아졸-2-일)부탄-1-온,[22] 1-(4-(1H-이미다졸-5-일)피페리딘-1-일)-4-(5-((2,3-디하이드로-1H-인덴-2-일)아미노)-1,3,4-옥사디아졸-2-일)부탄-1-온,[23] 1-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-2-((5-((2,3-디하이드로-1H-인덴-2-일)아미노)-1,3,4-티아디아졸-2-일)메톡시)에탄-1-온,[24] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-(5-(트리플루오로메틸)-1,3,4-옥사디아졸-2-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[25] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-(5-(디플루오로메틸)-1,3,4-옥사디아졸-2-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[26] 5-(5-(4-(1,2,4-옥사디아졸-3-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[27] 5-(5-(4-(1,3,4-옥사디아졸-2-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[28] 5-(5-(4-(1H-테트라졸-1-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[29] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-(4-메틸-1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[30] (E)-1-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-3-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)프로프-2-엔-1-온,[31] 5-(5-(4-(1-벤질-1H-1,2,3-트리아졸-5-일)피페리딘-1-일)옥사졸-2-일)-N-(2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[32] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-N-메틸피리미딘-2-아민,[33] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-(1-메틸-1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[34] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-(1-메틸-1H-1,2,3-트리아졸-4-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[35] N-인단-2-일-5-[3-[4-(1H-트리아졸-5-일)-1-피페리딜]-4,5-디하이드로이소옥사졸-5-일]피리미딘-2-아민,[36] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)이소옥사졸-5-일)-N-(2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[37] N-(5,6-디플루오로인단-2-일)-5-[3-[4-(1H-트리아졸-5-일)-1-피페리딜]-4,5-디하이드로이소옥사졸-5-일]피리미딘-2-아민,[38] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)이소옥사졸-5-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[39] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(5-플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[40] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)이소옥사졸-5-일)-N-(5-플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[41] N-[(3,5-디플루오로페닐)메틸]-5-[3-[4-(1H-트리아졸-5-일)-1-피페리딜]-4,5-디하이드로이소옥사졸-5-일]피리미딘-2-아민,[42] N-벤질-5-[3-[4-(1H-트리아졸-5-일)-1-피페리딜]-4,5-디하이드로이소옥사졸-5-일]피리미딘-2-아민,[43] N-[(3,4-디플루오로페닐)메틸]-5-[3-[4-(1H-트리아졸-5-일)-1-피페리딜]-4,5-디하이드로이소옥사졸-5-일]피리미딘-2-아민,[44] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(3,5-디클로로벤질)피리미딘-2-아민,[45] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(벤조[d][1,3]다이옥솔-5-일메틸)피리미딘-2-아민,[46] N-(1,3-벤조다이옥솔-5-일메틸)-5-[3-[4-(1H-트리아졸-5-일)-1-피페리딜]이소옥사졸-5-일]피리미딘-2-아민,[47] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(3,5-디클로로펜에틸)피리미딘-2-아민,[48] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(3-(메틸설포닐)벤질)피리미딘-2-아민,[49] 5-(3-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(4-(메틸설포닐)벤질)피리미딘-2-아민,[50] 5-(3-(4-(1H-테트라졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[51] 5-(3-(4-(5-(디플루오로메틸)-1,3,4-옥사디아졸-2-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[52] 5-(3-(4-(1H-테트라졸-5-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)-N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[53] N-(5-플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(3-(4-(5-(트리플루오로메틸)-1,3,4-옥사디아졸-2-일)피페리딘-1-일)-4,5-디하이드로이소옥사졸-5-일)피리미딘-2-아민,[54] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(2-메틸-4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[55] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(벤조[d][1,3]다이옥솔-5-일메틸)피리미딘-2-아민,[56] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(3,4-디클로로벤질)피리미딘-2-아민,[57] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(3,5-디플루오로벤질)피리미딘-2-아민,[58] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(3,4-디플루오로벤질)피리미딘-2-아민,[59] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(3,5-다이브로모벤질)피리미딘-2-아민,[60] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5-브로모-2,3-디하이드로-1H-인덴-2-일)-4-메틸피리미딘-2-아민,[61] 5-(5-(4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)-N-(5,6-다이브로모-2,3-디하이드로-1H-인덴-2-일)-4-메틸피리미딘-2-아민,[62] 5-(3-(4-(1H-1,2,3-트리아졸-4-일)피페리딘-1-일)프로필)-N-(2,3-디하이드로-1H-인덴-2-일)피리미딘-2-아민,[63] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-모폴리노피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민,[64] 1-(1-(5-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)-1,3,4-옥사디아졸-2-일)피페리딘-4-일)아제티딘-3-올,[65] 1-(5-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)-1,3,4-옥사디아졸-2-일)피페리딘-4-설폰아미드,[66] 5-(1-(5-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)-1,3,4-옥사디아졸-2-일)피페리딘-4-일)-1,3,4-옥사디아졸-2(3H)-온,[67] 1-(5-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)-1,3,4-옥사디아졸-2-일)피페리딘-4-카르복실산,[68] 2-(1-(5-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)-1,3,4-옥사디아졸-2-일)피페리딘-4-일)아세트산,[69] 1-(5-(2-((5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)아미노)피리미딘-5-일)-1,3,4-옥사디아졸-2-일)-N-히드록시피페리딘-4-카르복사미드,[70] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-메톡시-4-(1H-1,2,3-트리아졸-4-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민, 및[71] N-(5,6-디플루오로-2,3-디하이드로-1H-인덴-2-일)-5-(5-(4-플루오로-4-(1H-1,2,3-트리아졸-5-일)피페리딘-1-일)-1,3,4-옥사디아졸-2-일)피리미딘-2-아민으로 구성되는 군으로부터 선택되는 어느 하나의 화합물인 것을 특징으로 하는 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염.
- 제1항 내지 제11항 중 어느 한 항의 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 오토탁신 활성과 관련된 질환의 예방 또는 치료용 약학 조성물.
- 제12항에 있어서, 상기 오토탁신 활성과 관련된 질환이 섬유화 질환, 염증성 질환, 자가면역 질환, 호흡기 질환, 심혈관 질환, 대사성 질환, 암 및 암전이, 안구 질환, 담즙울체성 형태 및 다른 형태의 만성소양증, 및 급성 또는 만성 장기이식 거부반응으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 약학 조성물.
- 제1항 내지 제11항 중 어느 한 항의 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염을 포함하는, 특발성 폐 섬유증 (IPF), 간질성 폐질환, 간 섬유증, 간 경화증, 비알코올성 지방간염, 심근 및 혈관 섬유증, 신장 섬유증, 피부 섬유증, 사구체 경화증, 심근 및 혈관 섬유증 중에서 선택되는 섬유화 질환; 류머티스성 관절염, 골관절염, 아토피 피부염, 염증성 장 질환, 염증성 기도 질병, 만성 폐쇄성 폐질환(COPD) 및 천식 중에서 선택되는 염증성 질환; 다발성 경화증 및 경피증 중에서 선택되는 자가면역 질환; 석면 유도된 폐섬유증 및 급성 호흡곤란 증후군(ARDS) 중에서 선택되는 호흡기 질환; 동맥 경화증, 심근 경색, 동맥 및 폐 고혈압, 심장 부정맥, 뇌졸중 및 다른 혈관 손상 중에서 선택되는 심혈관 질환; 비만 및 당뇨병 중에서 선택되는 대사성 질환; 유방암, 난소암, 폐암, 전립선암, 중피종, 신경교종, 간암종, 위장관암, 췌장암, 및 이의 진행 및 전이 침입 중에서 선택되는 암 및 암전이; 증식성 및 비증식성(당뇨병성) 망막증, 건조 및 습한 연령 관련 황반 변성(AMD), 황반 부종, 중추 동맥/정맥 폐쇄, 외상성 손상, 및 녹내장 중에서 선택되는 안구 질환; 담즙울체성 형태 및 다른 형태의 만성소양증; 및 급성 또는 만성 장기이식 거부반응으로 이루어진 군으로부터 선택되는 것을 특징으로 하는 약학 조성물.
- 제1항 내지 제11항 중 어느 한 항의 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물 또는 이의 약학적으로 허용가능한 염을 포함하는, 방사선 유발 섬유증의 예방 또는 치료용 약학 조성물.
- 제1항 내지 제11항 중 어느 한 항의 피페리딘 유도체 화합물, 이의 수화물, 이의 용매화물, 또는 이의 약학적으로 허용가능한 염과, 약제학적으로 허용가능한 첨가제를 포함하는 것을 특징으로 하는 약학 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280038523.8A CN117396471A (zh) | 2021-10-01 | 2022-09-30 | 新的哌啶衍生物和包含其的用于抑制自分泌运动因子的药物组合物 |
EP22876950.1A EP4353720A1 (en) | 2021-10-01 | 2022-09-30 | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same |
AU2022356017A AU2022356017B2 (en) | 2021-10-01 | 2022-09-30 | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same |
CA3225327A CA3225327A1 (en) | 2021-10-01 | 2022-09-30 | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0130879 | 2021-10-01 | ||
KR20210130879 | 2021-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023055178A1 true WO2023055178A1 (ko) | 2023-04-06 |
Family
ID=85780846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/014774 WO2023055178A1 (ko) | 2021-10-01 | 2022-09-30 | 신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4353720A1 (ko) |
KR (1) | KR102524669B1 (ko) |
CN (1) | CN117396471A (ko) |
AU (1) | AU2022356017B2 (ko) |
CA (1) | CA3225327A1 (ko) |
WO (1) | WO2023055178A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018019929A1 (en) * | 2016-07-28 | 2018-02-01 | Idorsia Pharmaceuticals Ltd | Piperidine cxcr7 receptor modulators |
KR20190039537A (ko) * | 2011-04-21 | 2019-04-12 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
KR20210075110A (ko) * | 2018-10-10 | 2021-06-22 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 질소 함유 헤테로방향족 유도체의 조절제, 이의 제조 방법 및 이의 용도 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100917511B1 (ko) * | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
EA037928B1 (ru) | 2014-03-26 | 2021-06-08 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
-
2022
- 2022-09-30 CN CN202280038523.8A patent/CN117396471A/zh active Pending
- 2022-09-30 AU AU2022356017A patent/AU2022356017B2/en active Active
- 2022-09-30 EP EP22876950.1A patent/EP4353720A1/en active Pending
- 2022-09-30 CA CA3225327A patent/CA3225327A1/en active Pending
- 2022-09-30 WO PCT/KR2022/014774 patent/WO2023055178A1/ko active Application Filing
- 2022-09-30 KR KR1020220125024A patent/KR102524669B1/ko active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190039537A (ko) * | 2011-04-21 | 2019-04-12 | 재단법인 한국파스퇴르연구소 | 소염 화합물 |
WO2018019929A1 (en) * | 2016-07-28 | 2018-02-01 | Idorsia Pharmaceuticals Ltd | Piperidine cxcr7 receptor modulators |
KR20210075110A (ko) * | 2018-10-10 | 2021-06-22 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 질소 함유 헤테로방향족 유도체의 조절제, 이의 제조 방법 및 이의 용도 |
Non-Patent Citations (2)
Title |
---|
DATABASE Registry 12 September 2004 (2004-09-12), "CN -2-Pyrimidinamine, 5-[[4-(1,2,4-oxadiazol-3-yl)-1-piperidinyl]methyl]-N- (phenylmethyl)-(CA INDEX NAME)", XP093055302, retrieved from STN express Database accession no. RN 1622649-17-5 * |
DATABASE Registry 12 September 2004 (2004-09-12), "CN -2-Pyrimidinamine, N-(phenylmethyl)-5-[[4-(1H-1,2,4-triazol-5-yl)-1- piperidinyl]methyl]-(CA INDEX NAME)", XP093055301, retrieved from STN express Database accession no. RN 1622506-83-5 * |
Also Published As
Publication number | Publication date |
---|---|
CA3225327A1 (en) | 2023-04-06 |
AU2022356017B2 (en) | 2024-05-30 |
EP4353720A1 (en) | 2024-04-17 |
KR20230047919A (ko) | 2023-04-10 |
CN117396471A (zh) | 2024-01-12 |
KR102524669B1 (ko) | 2023-04-21 |
AU2022356017A1 (en) | 2024-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020384121B2 (en) | GLP-1 receptor agonist and use thereof | |
WO2021187886A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2019190259A1 (ko) | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 | |
WO2018139903A1 (ko) | 피리미딘 화합물 및 그의 의약 용도 | |
WO2022216094A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2017142325A1 (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
WO2020096372A1 (ko) | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 | |
EP2989093A1 (en) | Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | |
WO2019074241A1 (ko) | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 | |
EP2331529A2 (en) | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof | |
WO2018151562A2 (ko) | Jnk 저해 활성을 갖는 신규한 벤즈이미다졸 유도체 및 이의 용도 | |
WO2011049274A1 (en) | Imidazole derivatives and compositions for treating melanoma | |
WO2020022787A1 (ko) | Jnk 저해 활성을 갖는 신규한 이미다졸 유도체 및 이를 포함하는 약학적 조성물 | |
WO2023055178A1 (ko) | 신규한 피페리딘 유도체 및 이를 포함하는 오토탁신 저해용 약학 조성물 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
WO2021172871A1 (ko) | 단백질 인산화 효소 저해 활성을 갖는 신규한 이미다졸 유도체 및 이의 용도 | |
WO2022139304A1 (ko) | Sos1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도 | |
WO2020263058A1 (ko) | 아미노시아노피리딘 유도체 및 그의 용도 | |
WO2021137665A1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
WO2019098785A1 (ko) | 7-아미노-1h-인돌-5-카르복사미드 유도체 및 이의 용도 | |
WO2018021762A1 (ko) | 신규 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
WO2024019597A1 (ko) | 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물 | |
WO2024112120A1 (ko) | 신규한 c-MET 단백질 리간드를 포함하는 디그레이더 및 이를 포함하는 약학 조성물 | |
WO2021182914A1 (ko) | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 | |
WO2023101326A1 (ko) | 오토탁신 저해제로서의 신규 화합물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22876950 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18560806 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/013961 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280038523.8 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023132551 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023025064 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2023577513 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022356017 Country of ref document: AU Ref document number: AU2022356017 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3225327 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022876950 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022876950 Country of ref document: EP Effective date: 20240111 |
|
ENP | Entry into the national phase |
Ref document number: 2022356017 Country of ref document: AU Date of ref document: 20220930 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523451815 Country of ref document: SA |
|
ENP | Entry into the national phase |
Ref document number: 112023025064 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231129 |